BioSpace News Archive

Drug Development

Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).

September 26, 2018
·
11 min read
Business

HERNDON TEEN AWARDED $50,000FOR RESEARCH ON PERSONALIZED, TARGETED TREATMENTS FOR CANCERPATIENTS

Kavya Kopparaputo be Named a 2018 Davidson Fellow

September 26, 2018
·
3 min read
Medtronic Builds on TAVR Clinical Evidence Portfolio with Five-Year CoreValve Durability Data and Complete Two-Year Outcomes in Intermediate Risk Aortic Stenosis Patients

TCT18: New Five-Year Data with CoreValve TAVR System Suggests Durability Over Time, While Complete Results from the SURTAVI Trial Show Benefits of TAVR in Intermediate Risk Patients

September 26, 2018
·
5 min read
BioForest

VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy

Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer

September 26, 2018
·
9 min read
Business

2018 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €238M AND SIGNIFICANT ADVANCES IN THE CLINICAL DEVELOPMENT OF ELAFIBRANOR

Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.

September 26, 2018
·
26 min read
Business

GENFIT: Gearing Up for 2019 with Organizational Changes

GENFIT today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company.

September 26, 2018
·
7 min read
Policy

California Life Sciences Association Applauds Governor Brown for Signing SB 1121, Legislation That Protects Clinical Trials and Patient Access in California

SB 1121 Contains Common Sense, Bipartisan Fix to Unintended Consequences of Data Privacy Bill

September 26, 2018
·
2 min read
Lonza’s Capital Markets Day 2018 Outlines Sustainable Growth Plans Through Focus and Investment

Lonza is holding a series of events as part of this year’s Capital Markets Day from 24-26 September in Zurich and Visp (CH).

September 26, 2018
·
4 min read